AIMS: The aim was to test the hypothesis that carotid artery plaque expression of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) predicts cardiac events. METHODS AND RESULTS: Prospective cohort study of 162 consecutive patients undergoing elective carotid endarterectomy. Lipoprotein-associated phospholipase A(2) content was quantified by immunoblotting and lysophosphatidylcholine (lysoPC) by liquid chromatography tandem mass spectrometry. Additional biomolecular profiling by immunoblotting included C-reactive protein, p67phox, and matrix metalloproteinase-2 and -9. Macrophage plaque content was determined by quantitative immunostaining, plaque collagen content by quantitative Sirius red staining. Follow-up for cardiac death and non-fatal acute myocardial infarction was accomplished over a period of 48 +/- 14 months. Expression of Lp-PLA(2) and lysoPC was higher in carotid plaques of patients with than without cardiac events [median 1.6 (25th, 75th percentile 0.9, 2.5) vs. 0.8 (0.5, 2.0), P = 0.01 and 413 (281, 443) vs. 226 (96, 351) mmol/L, P = 0.03]. Smoking and point increase in carotid Lp-PLA(2) expression but no other traditional cardiovascular risk factor, histological or molecular marker remained predictive of cardiac events in the multivariate Cox proportional hazard analyses [HR 3.65 (1.36-9.83), P = 0.01 and HR 1.34 (1.01-1.77), P = 0.039]. Carotid plaque Lp-PLA(2) expression above the median constituted a more than three times higher risk for cardiac events [HR 3.39 (1.13-10.17), P = 0.03]. CONCLUSION: Lipoprotein-associated phospholipase A(2) expression in carotid artery plaques is a predictor of long-term cardiac outcome. The current study supports the concept of atherosclerosis as a systemic disease with multi-focal complications and personalized medicine.
AIMS: The aim was to test the hypothesis that carotid artery plaque expression of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) predicts cardiac events. METHODS AND RESULTS: Prospective cohort study of 162 consecutive patients undergoing elective carotid endarterectomy. Lipoprotein-associated phospholipase A(2) content was quantified by immunoblotting and lysophosphatidylcholine (lysoPC) by liquid chromatography tandem mass spectrometry. Additional biomolecular profiling by immunoblotting included C-reactive protein, p67phox, and matrix metalloproteinase-2 and -9. Macrophage plaque content was determined by quantitative immunostaining, plaque collagen content by quantitative Sirius red staining. Follow-up for cardiac death and non-fatal acute myocardial infarction was accomplished over a period of 48 +/- 14 months. Expression of Lp-PLA(2) and lysoPC was higher in carotid plaques of patients with than without cardiac events [median 1.6 (25th, 75th percentile 0.9, 2.5) vs. 0.8 (0.5, 2.0), P = 0.01 and 413 (281, 443) vs. 226 (96, 351) mmol/L, P = 0.03]. Smoking and point increase in carotid Lp-PLA(2) expression but no other traditional cardiovascular risk factor, histological or molecular marker remained predictive of cardiac events in the multivariate Cox proportional hazard analyses [HR 3.65 (1.36-9.83), P = 0.01 and HR 1.34 (1.01-1.77), P = 0.039]. Carotid plaque Lp-PLA(2) expression above the median constituted a more than three times higher risk for cardiac events [HR 3.39 (1.13-10.17), P = 0.03]. CONCLUSION:Lipoprotein-associated phospholipase A(2) expression in carotid artery plaques is a predictor of long-term cardiac outcome. The current study supports the concept of atherosclerosis as a systemic disease with multi-focal complications and personalized medicine.
Authors: Emmanouil S Brilakis; Joseph P McConnell; Ryan J Lennon; Ahmad A Elesber; Jeffrey G Meyer; Peter B Berger Journal: Eur Heart J Date: 2004-11-29 Impact factor: 29.983
Authors: C H MacPhee; K E Moores; H F Boyd; D Dhanak; R J Ife; C A Leach; D S Leake; K J Milliner; R A Patterson; K E Suckling; D G Tew; D M Hickey Journal: Biochem J Date: 1999-03-01 Impact factor: 3.857
Authors: Eric H Yang; Joseph P McConnell; Ryan J Lennon; Gregory W Barsness; Geralyn Pumper; Stacy J Hartman; Charanjit S Rihal; Lilach O Lerman; Amir Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2005-10-20 Impact factor: 8.311
Authors: Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett Journal: Circulation Date: 2004-02-02 Impact factor: 29.690
Authors: Alexandros D Tselepis; George Hahalis; Constantinos C Tellis; Eleni C Papavasiliou; Panagiota T Mylona; Alexandra Kourakli; Dimitrios C Alexopoulos Journal: J Lipid Res Date: 2010-07-12 Impact factor: 5.922
Authors: Chiara Giannarelli; Matilde Alique; David T Rodriguez; Dong Kwon Yang; Dongtak Jeong; Claudia Calcagno; Randolph Hutter; Antoine Millon; Jason C Kovacic; Thomas Weber; Peter L Faries; Gerald A Soff; Zahi A Fayad; Roger J Hajjar; Valentin Fuster; Juan J Badimon Journal: Circulation Date: 2014-08-12 Impact factor: 29.690
Authors: Stuart G Snowden; Dmitry Grapov; Magnus Settergren; Fabio Luiz D'Alexandri; Jesper Z Haeggström; Oliver Fiehn; Tuulia Hyötyläinen; Theresa L Pedersen; John W Newman; Matej Orešič; John Pernow; Craig E Wheelock Journal: Circ Cardiovasc Genet Date: 2014-12
Authors: Constantinos C Tellis; Eliza Moutzouri; Moses Elisaf; Robert L Wolfert; Alexandros D Tselepis Journal: J Lipid Res Date: 2013-10-03 Impact factor: 5.922
Authors: Andreas J Flammer; Mario Gössl; Robert Jay Widmer; Martin Reriani; Ryan Lennon; Darrell Loeffler; Sarah Shonyo; Robert D Simari; Lilach O Lerman; Sundeep Khosla; Amir Lerman Journal: Eur Heart J Date: 2012-07-31 Impact factor: 29.983